578 related articles for article (PubMed ID: 30611457)
1. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
[TBL] [Abstract][Full Text] [Related]
3. Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies.
Gafter-Gvili A; Tibau A; Raanani P; Shepshelovich D
Acta Haematol; 2020; 143(1):73-77. PubMed ID: 31167178
[TBL] [Abstract][Full Text] [Related]
4. Twenty Years of Targeted and Biologic Immunomodulatory Drugs: Postmarketing Modifications of Drug Labels Approved by the US Food and Drug Administration.
Berman J; Yavne Y; Edel Y; Elkayam O; Furer V; Shepshelovich D
Mayo Clin Proc; 2022 Aug; 97(8):1512-1522. PubMed ID: 35933136
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018.
Fan M; Chan AYL; Yan VKC; Tong X; Lau LKW; Wan EYF; Tam EYT; Ip P; Lum TY; Wong ICK; Li X
Orphanet J Rare Dis; 2022 Jan; 17(1):3. PubMed ID: 34983612
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration : A Cohort Study.
Tau N; Yahav D; Shepshelovich D
Ann Intern Med; 2020 Sep; 173(6):445-449. PubMed ID: 32716700
[TBL] [Abstract][Full Text] [Related]
7. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
8. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
Botelho SF; Martins MA; Vieira LB; Reis AM
J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
10. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014.
Pinnow E; Amr S; Bentzen SM; Brajovic S; Hungerford L; St George DM; Dal Pan G
Clin Pharmacol Ther; 2018 Aug; 104(2):390-400. PubMed ID: 29266187
[TBL] [Abstract][Full Text] [Related]
11. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
Mostaghim SR; Gagne JJ; Kesselheim AS
BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
[No Abstract] [Full Text] [Related]
12. Drug-review deadlines and safety problems.
Carpenter D; Zucker EJ; Avorn J
N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
[TBL] [Abstract][Full Text] [Related]
13. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
Downing NS; Shah ND; Aminawung JA; Pease AM; Zeitoun JD; Krumholz HM; Ross JS
JAMA; 2017 May; 317(18):1854-1863. PubMed ID: 28492899
[TBL] [Abstract][Full Text] [Related]
14. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
Ikeda J; Kaneko M; Narukawa M
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
[TBL] [Abstract][Full Text] [Related]
15. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
Naci H; Smalley KR; Kesselheim AS
JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
[TBL] [Abstract][Full Text] [Related]
17. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
[TBL] [Abstract][Full Text] [Related]
18. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
19. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
